Clinical Trial: Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07067905) titled 'Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma' on July 07.

Brief Summary: A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.

Study Start Date: June 27

Study Type: INTERVENTIONAL

Condition: Clear Cell Renal Cell Carcinoma and Glioblastoma

Intervention: DRUG: 68Ga-XT771

68Ga-X...